Patents by Inventor Nathalie Demotte

Nathalie Demotte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for modulating activity of T lymphocytes
    Patent number: 8951747
    Abstract: The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Nathalie Demotte, Pierre Van Der Bruggen, Thierry Boon-Falleur
  • METHOD FOR MODULATING ACTIVITY OF T LYMPHOCYTES
    Publication number: 20120196363
    Abstract: The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.
    Type: Application
    Filed: March 26, 2012
    Publication date: August 2, 2012
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Nathalie DEMOTTE, Pierre Van Der Bruggen, Thierry Boon-Falleur
  • METHOD FOR MODULARTING ACTIVITY OF T LYMPHOCYTES
    Publication number: 20100136597
    Abstract: The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.
    Type: Application
    Filed: March 3, 2008
    Publication date: June 3, 2010
    Inventors: Nathalie Demotte, Peirre Van Der Druggen, Thierry Boon-Falleur
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 7351409
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: April 1, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Tumor antigens and CTL clones isolated by a novel procedure
    Publication number: 20040185033
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Application
    Filed: January 7, 2004
    Publication date: September 23, 2004
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6710172
    Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 23, 2004
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6531451
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: March 11, 2003
    Assignees: Ludwig Institute for Cancer Research, Universite Catholique de Louvain
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catia Traversari, Vincent Stroobant, Guy Cornelis, Thiery Boon-Falleur, Pierre van der Bruggen
  • MAGE antigenic peptides which bind HLA-B35 and HLA-B44
    Publication number: 20020164654
    Abstract: The invention provides antigenic peptides derived from MAGE-A1 polypeptides and presented by HLA-B35 and HLA-B44 molecules. Antigenic peptides derived from MAGE-A3 polypeptides and presented by HLA-B35 molecules also are provided. Methods for diagnosis and treatment which involve the polypeptides also are provided.
    Type: Application
    Filed: January 19, 2001
    Publication date: November 7, 2002
    Inventors: Rosalie Luiten, Thierry Boon-Falleur, Pierre Van der Bruggen, Vincent Stroobant, Nathalie Demotte, Erwin Schultz
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6407063
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: June 18, 2002
    Assignees: Ludwig Institute for Cancer Research, Universite Catholique de Louvain
    Inventors: Rosalie Luiten, Marie-Therese Duffour, Nathalie Demotte, Pierre van der Bruggan, Guy Cornelius, Vincent Stroobant, Christophe Lurquin, Thierry Boon-Falleur